These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 24206433

  • 1. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 2. Review article: the management of paediatric nonalcoholic fatty liver disease.
    Mitchel EB, Lavine JE.
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1155-70. PubMed ID: 25267322
    [Abstract] [Full Text] [Related]

  • 3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 4. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Jun; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 5. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 6. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR, Torres DM, Harrison SA.
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [Abstract] [Full Text] [Related]

  • 7. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 8. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 Jun; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 9. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, Sahebkar A.
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [Abstract] [Full Text] [Related]

  • 10. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, Karagiannis A.
    Curr Vasc Pharmacol; 2018 Aug; 16(3):246-253. PubMed ID: 28676019
    [Abstract] [Full Text] [Related]

  • 11. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I.
    Pol Merkur Lekarski; 2017 Nov 23; 43(257):237-242. PubMed ID: 29231919
    [Abstract] [Full Text] [Related]

  • 12. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A, Akhter A.
    Ann Hepatol; 2017 Nov 23; 16(4):538-547. PubMed ID: 28611274
    [Abstract] [Full Text] [Related]

  • 13. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.
    Caravatto PP, Cohen R.
    Curr Atheroscler Rep; 2017 Oct 07; 19(11):45. PubMed ID: 28986720
    [Abstract] [Full Text] [Related]

  • 14. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan 07; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 15. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA, Loomba R.
    J Clin Exp Hepatol; 2012 Jun 07; 2(2):156-73. PubMed ID: 25755424
    [Abstract] [Full Text] [Related]

  • 16. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM.
    Aliment Pharmacol Ther; 2008 Jul 07; 28(1):2-12. PubMed ID: 18410557
    [Abstract] [Full Text] [Related]

  • 17. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A, Wong RJ, Harrison SA.
    Clin Gastroenterol Hepatol; 2015 Nov 07; 13(12):2062-70. PubMed ID: 26226097
    [Abstract] [Full Text] [Related]

  • 18. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Vuppalanchi R, Chalasani N.
    Hepatology; 2009 Jan 07; 49(1):306-17. PubMed ID: 19065650
    [Abstract] [Full Text] [Related]

  • 19. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
    Bugianesi E, Marzocchi R, Villanova N, Marchesini G.
    Best Pract Res Clin Gastroenterol; 2004 Dec 07; 18(6):1105-16. PubMed ID: 15561641
    [Abstract] [Full Text] [Related]

  • 20. Non-alcoholic steatohepatitis in children.
    Nanda K.
    Pediatr Transplant; 2004 Dec 07; 8(6):613-8. PubMed ID: 15598336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.